My watch list
my.bionity.com  
Login  

32 Newest Publications about the topic hemophilia

rss

Intravenous administration of Factor VIII–O-Phospho-L-Serine (OPLS) complex reduces immunogenicity and preserves pharmacokinetics of the therapeutic protein

26-10-2014 | Author(s): Puneet Gaitonde , Vivek S. Purohit , Sathy V. Balu-Iyer, European Journal of Pharmaceutical Science, 2014

Publication date: Available online 20 October 2014 Source:European Journal of Pharmaceutical Sciences Author(s): Puneet Gaitonde , Vivek S. Purohit , Sathy V. Balu-Iyer Hemophilia A is a bleeding disorder caused by the deficiency of an important coagulation factor; Factor VIII (FVIII). ...

more

The extraordinary career of Professor Dr. Simon van Creveld

30-09-2014 | Paul J. W. Stoelinga, Walter E. Berdon, M. Michael Cohen, American Journal of Medical Genetics Part A, 2014

Simon van Creveld received both the MD and PhD degrees and had a multifaceted medical and scientific education at many hospitals and research institutes in the Netherlands, Germany, and the UK. He and his wife were the first to develop insulin for the Netherlands. His major interests were in ...

more

O‐Phospho‐l‐Serine mediates Hyporesponsiveness toward FVIII in Hemophilia A‐Murine Model by Inducing Tolerogenic Properties in Dendritic Cells

30-09-2014 | Anas M. Fathallah, Radha Ramakrishnan, Sathy V. Balu‐Iyer, Journal of Pharmaceutical Sciences, 2014

The clinical use of therapeutic proteins can be complicated by the development of anti‐product antibodies. We have previously observed that O‐phospho‐l‐serine (OPLS) reduced antibody response to FVIII in Hemophilia‐A (HA) mice. However, the mechanism underlying this observation is not clear. We ...

more

Delivery of Full-Length Factor VIII Using a piggyBac Transposon Vector to Correct a Mouse Model of Hemophilia A

15-08-2014 | Hideto Matsui et al., PLoS ONE, 2014

by Hideto Matsui, Naoko Fujimoto, Noriko Sasakawa, Yasuhide Ohinata, Midori Shima, Shinya Yamanaka, Mitsuhiko Sugimoto, Akitsu Hotta Viral vectors have been used for hemophilia A gene therapy. However, due to its large size, full-length Factor VIII (FVIII) cDNA has not been successfully ...

more

The prevalence of neutralizing antibodies against adeno‐associated virus capsids is reduced in young Japanese individuals

17-10-2013 | Jun Mimuro, Hiroaki Mizukami, Midori Shima, Tadashi Matsushita, Masashi Taki, Shinji Muto, Satoshi Higasa, Michio Sa ..., Journal of Medical Virology, 2013

Abstract Pre‐existing antibodies against adeno‐associated virus (AAV), caused by natural AAV infections, interfere with recombinant AAV vector‐mediated gene transfer. We studied the prevalence of neutralizing antibodies against AAV serotypes 1, 2, 5, 8, and 9 in healthy subjects (n = 85) and ...

more

Polymorphisms in the F8 Gene and MHC-II Variants as Risk Factors for the Development of Inhibitory Anti-Factor VIII Antibodies during the Treatment of Hemophilia A: A Computational Assessment

16-05-2013 | Gouri Shankar Pandey et al., PLoS Computational Biology, 2013

by Gouri Shankar Pandey, Chen Yanover, Tom E. Howard, Zuben E. Sauna The development of neutralizing anti-drug-antibodies to the Factor VIII protein-therapeutic is currently the most significant impediment to the effective management of hemophilia A. Common non-synonymous single nucleotide ...

more

A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A

01-05-2013 | Jérôme Lane; Paul J. McLaren; Lucy Dorrell; Kevin V. Shianna; Amanda Stemke; Kimberly Pelak; Stephen Moore; Johannes ..., Human Molecular Genetics, 2013

Human genetic variation contributes to differences in susceptibility to HIV-1 infection. To search for novel host resistance factors, we performed a genome-wide association study (GWAS) in hemophilia patients highly exposed to potentially contaminated factor VIII infusions. Individuals with ...

more

Anti‐inflammatory/regulatory cytokine microenvironment mediated by IL‐4 and IL‐10 coordinates the immune response in hemophilia A patients infected chronically with Hepatitis C virus

16-04-2013 | João Paulo Pimentel, Daniel Gonçalves Chaves, Ana Ruth Silva Araújo, Erbênia Maria Martins de Araújo, Liziara da Sil ..., Journal of Medical Virology, 2013

Abstract In the past decades patients with hemophilia were infected commonly by hepatitis C virus (HCV) and a significant number of patients are infected chronically. Focusing on the role of the immune system for controlling and or maintaining HCV infection, the leukocyte and cytokine profiles ...

more

The clot thickens for long-lasting drugs that stop hemophilia short

06-02-2013 | Alisa Opar, Nature Medicine, 2013

Nature Medicine 19, 121 (2013). doi:10.1038/nm0213-121 Author: Alisa Opar

more

Domain organization of membrane‐bound factor VIII

17-01-2013 | Svetla Stoilova‐McPhie, Gillian C. Lynch, Steven Ludtke, B. Montgomery Pettitt, Biopolymers, 2013

Abstract Factor VIII (FVIII) is the blood coagulation protein when defective or deficient causes for hemophilia A, a severe hereditary bleeding disorder. Activated FVIII (FVIIIa) is the co‐factor to the serine protease Factor IXa (FIXa) within the membrane‐bound Tenase complex, responsible for ...

more

Page 1 From 4
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE